Low-dose sirolimus in retroperitoneal lymphangioleiomyomas

Kamonpun Ussavarungsi, Archana T. Laroia, Charles Dwayne Burger

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Lymphangioleiomyomatosis (LAM) is a rare disease associated with cystic lung destruction and abdominal tumors, including lymphangioleiomyomas, which frequently occur in the retroperitoneal region. Sirolimus therapy is currently recommended for LAM patients with abnormal or declining lung function with an adjusted dose to maintain a serum trough level of 5-15 ng/mL. We describe a significant reduction of retroperitoneal lymphangioleiomyomas after treatment with low-dose sirolimus therapy (serum trough level <5 ng/mL) in a patient with sporadic LAM.

Original languageEnglish (US)
Pages (from-to)349-352
Number of pages4
JournalLung India
Volume36
Issue number4
DOIs
StatePublished - Jul 1 2019

Fingerprint

Lymphangiomyoma
Lymphangioleiomyomatosis
Sirolimus
Lung
Rare Diseases
Serum
Therapeutics
Neoplasms

Keywords

  • Low-dose sirolimus
  • Lymphangioleimyomas
  • Lymphangioleiomyomatosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Low-dose sirolimus in retroperitoneal lymphangioleiomyomas. / Ussavarungsi, Kamonpun; Laroia, Archana T.; Burger, Charles Dwayne.

In: Lung India, Vol. 36, No. 4, 01.07.2019, p. 349-352.

Research output: Contribution to journalReview article

Ussavarungsi, Kamonpun ; Laroia, Archana T. ; Burger, Charles Dwayne. / Low-dose sirolimus in retroperitoneal lymphangioleiomyomas. In: Lung India. 2019 ; Vol. 36, No. 4. pp. 349-352.
@article{2df183c306b84abfa9a807acf8561cc1,
title = "Low-dose sirolimus in retroperitoneal lymphangioleiomyomas",
abstract = "Lymphangioleiomyomatosis (LAM) is a rare disease associated with cystic lung destruction and abdominal tumors, including lymphangioleiomyomas, which frequently occur in the retroperitoneal region. Sirolimus therapy is currently recommended for LAM patients with abnormal or declining lung function with an adjusted dose to maintain a serum trough level of 5-15 ng/mL. We describe a significant reduction of retroperitoneal lymphangioleiomyomas after treatment with low-dose sirolimus therapy (serum trough level <5 ng/mL) in a patient with sporadic LAM.",
keywords = "Low-dose sirolimus, Lymphangioleimyomas, Lymphangioleiomyomatosis",
author = "Kamonpun Ussavarungsi and Laroia, {Archana T.} and Burger, {Charles Dwayne}",
year = "2019",
month = "7",
day = "1",
doi = "10.4103/lungindia.lungindia_433_18",
language = "English (US)",
volume = "36",
pages = "349--352",
journal = "Lung India",
issn = "0970-2113",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "4",

}

TY - JOUR

T1 - Low-dose sirolimus in retroperitoneal lymphangioleiomyomas

AU - Ussavarungsi, Kamonpun

AU - Laroia, Archana T.

AU - Burger, Charles Dwayne

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Lymphangioleiomyomatosis (LAM) is a rare disease associated with cystic lung destruction and abdominal tumors, including lymphangioleiomyomas, which frequently occur in the retroperitoneal region. Sirolimus therapy is currently recommended for LAM patients with abnormal or declining lung function with an adjusted dose to maintain a serum trough level of 5-15 ng/mL. We describe a significant reduction of retroperitoneal lymphangioleiomyomas after treatment with low-dose sirolimus therapy (serum trough level <5 ng/mL) in a patient with sporadic LAM.

AB - Lymphangioleiomyomatosis (LAM) is a rare disease associated with cystic lung destruction and abdominal tumors, including lymphangioleiomyomas, which frequently occur in the retroperitoneal region. Sirolimus therapy is currently recommended for LAM patients with abnormal or declining lung function with an adjusted dose to maintain a serum trough level of 5-15 ng/mL. We describe a significant reduction of retroperitoneal lymphangioleiomyomas after treatment with low-dose sirolimus therapy (serum trough level <5 ng/mL) in a patient with sporadic LAM.

KW - Low-dose sirolimus

KW - Lymphangioleimyomas

KW - Lymphangioleiomyomatosis

UR - http://www.scopus.com/inward/record.url?scp=85068853823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068853823&partnerID=8YFLogxK

U2 - 10.4103/lungindia.lungindia_433_18

DO - 10.4103/lungindia.lungindia_433_18

M3 - Review article

VL - 36

SP - 349

EP - 352

JO - Lung India

JF - Lung India

SN - 0970-2113

IS - 4

ER -